We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

China proposes new rules to address perceived anti-competitive practices in the pharmaceutical industry

16 August 2017

On 14 August 2017, the National Development and Reform Commission ("NDRC") released a draft of the Guidelines on Pricing Conduct by Business Operators for Drugs in Shortage and Active Pharmaceutical Ingredients ("Draft Guidelines").  NDRC is seeking comments on the Draft Guidelines until mid-September. 

One day later, NDRC made public the full text of its decisions against two local companies for excessive pricing and refusal to supply active pharmaceutical ingredients (see here and here), confirming its determination to use antitrust as a key enforcement tool in the pharmaceutical industry.

Click here for the full article.


Loading data